Colony and Single Cell Level Analysis of the Heterogeneous Response of Cryptococcus neoformans to Fluconazole

Sophie Altamirano1, Charles Simmons1, Lukasz Kozubowski1

  • 1Department of Genetics and Biochemistry, Clemson University, Clemson, SC, United States.

Insights

Cryptococcus neoformans exhibits drug resistance to fluconazole (FLC) due to cell subpopulations developing aneuploidy. This study examines FLC resistance heterogeneity, revealing variable ergosterol levels and proposing a model for response dynamics.

Area of Science:

  • Medical Mycology
  • Antimicrobial Resistance
  • Cellular Biology

Background:

  • Cryptococcus neoformans causes life-threatening meningitis in immunocompromised patients.
  • Fluconazole (FLC) is a standard antifungal treatment, but resistance can emerge.
  • The mechanisms driving differential FLC resistance in isogenic C. neoformans populations are not fully understood.

Purpose of the Study:

  • To systematically investigate the heterogeneous response of C. neoformans to FLC at both colony and single-cell levels.
  • To identify factors contributing to the emergence of FLC-resistant subpopulations.
  • To model the dynamics of FLC resistance based on drug concentration and growth conditions.

Main Methods:

  • Exposure of C. neoformans populations to varying concentrations of FLC on semi-solid media.
  • Analysis of colony formation and size to differentiate resistant and non-resistant subpopulations.
  • Assessment of ergosterol levels at the plasma membrane in response to FLC.

Main Results:

  • Heterogeneity in FLC response is linked to variable ergosterol depletion.
  • Two distinct outcomes observed: colonies of non-resistant survivors and larger colonies of FLC-resistant cells.
  • FLC-resistant colonies are often aneuploid for specific chromosomal regions.

Conclusions:

  • C. neoformans displays significant phenotypic heterogeneity in response to FLC.
  • A proposed model accounts for the influence of FLC concentration and growth parameters on resistance.
  • Findings offer insights for optimizing FLC therapy and managing cryptococcosis.